EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic strategies for MMAE ‐resistant bladder cancer through DPP4 inhibition

Gang Li, Shuichi Tatarano, Hirofumi Yoshino iD, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida iD

Molecular Oncology · 2026

DOI: 10.1002/1878-0261.70187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Gang Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monomethyl auristatin E (MMAE) is used as the cytotoxic payload for enfortumab vedotin (EV) in the treatment of locally advanced and metastatic bladder cancer (BC). However, the development of resistance to MMAE in BC is a therapeutic problem. To explore the mechanism of resistance to MMAE in BC, we established MMAE‐resistant BC cells (MR‐BCs). RNA sequencing analysis showed that the expression of dipeptidyl peptidase 4 (DPP4, also called CD26) increased significantly in MR‐BCs compared with parental BC cells. Knock down of DPP4 expression using small interfering RNA inhibited the viability of MR‐BCs. In addition, the DPP4 inhibitor sitagliptin suppressed the proliferation, migration, and invasion of BC cells, and cotreatment with MMAE effectively induced cell apoptosis, arrested cells in the G 2 M phase of the cell cycle, increased reactive oxygen species production by inhibiting the AKT pathway, and significantly inhibited the in vivo growth of MMAE‐resistant cells. This study provides insights into the use of DPP4 inhibitors as a treatment strategy for MMAE‐resistant BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDrug Resistance, NeoplasmOligopeptidesHumansCell Line, TumorAnimalsApoptosisCell ProliferationSitagliptin PhosphateMiceMice, NudeCell MovementXenograft Model Antitumor AssaysFemaleReactive Oxygen SpeciesMice, Inbred BALB CProto-Oncogene Proteins c-akt

Stichwörter der Autor:innen

AKTbladder cancerdipeptidyl peptidase 4monomethyl auristatin Esitagliptin

Substanzen

Dipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsOligopeptidesSitagliptin PhosphateDPP4 protein, humanReactive Oxygen SpeciesProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Japan.

ORCID-Profile: Hirofumi Yoshino, Hideki Enokida

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Li, G., Tatarano, S., Yoshino, H., Saito, S., Tominaga, M., Arima, J., Fukuda, I., Sakaguchi, T., Matsushita, R., Yamada, Y., & Enokida, H. (2026). Therapeutic strategies for MMAE ‐resistant bladder cancer through DPP4 inhibition. Molecular Oncology. https://doi.org/10.1002/1878-0261.70187

Vancouver

Li G, Tatarano S, Yoshino H, Saito S, Tominaga M, Arima J, et al. Therapeutic strategies for MMAE ‐resistant bladder cancer through DPP4 inhibition. Molecular Oncology. 2026. doi:10.1002/1878-0261.70187

BibTeX
@article{Li2026,
  author = {Li, Gang and Tatarano, Shuichi and Yoshino, Hirofumi and Saito, Saeki and Tominaga, Mitsuhiko and Arima, Junya and Fukuda, Ikumi and Sakaguchi, Takashi and Matsushita, Ryosuke and Yamada, Yasutoshi and Enokida, Hideki},
  title = {Therapeutic strategies for MMAE ‐resistant bladder cancer through DPP4 inhibition},
  journal = {Molecular Oncology},
  year = {2026},
  doi = {10.1002/1878-0261.70187}
}
Kostenlos starten →